Skip to main navigation
MIRUM

Header Menu

  • Who We Are
    • About Mirum
    • Leadership
    • Board of Directors
  • Programs
    • Pipeline
    • Maralixibat
    • Volixibat
    • Publications & Presentations
  • Patients & Families
    • Clinical Trials
    • Expanded Access
    • Progressive Familial Intrahepatic Cholestasis (PFIC)
    • Alagille Syndrome (ALGS)
    • Biliary Atresia (BA)
    • Intrahepatic Cholestasis of Pregnancy (ICP)
    • Primary Sclerosing Cholangitis (PSC)
  • Investors & Media
    • News Releases
    • Events and Presentations
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financials & Filings
      • SEC Filing
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers
  • Contact Us
  • Menu

Investor Relations

  • News Releases
  • Events and Presentations
  • Corporate Governance
    • Documents & Charters
    • Board of Directors
    • Management
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Analyst Coverage
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
  • Shareholder Services
    • Investor FAQs
    • Contact IR
    • Email Alerts

Investor Tools

  • Print

    Print

  • RSS Feeds

    RSS Feeds

  • Email Alerts

    Email Alerts

  • Search

    Search

  • Contact IR

    Contact IR

  • Email Page

    Email Page

News Release Details

Mirum Pharmaceuticals Announces Pricing of Public Offering

January 8, 2020 at 8:15 PM EST
PDF Version

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 8, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the pricing of its public offering of 2,400,000 shares of its common stock at a price to the public of $20.00 per share. The gross proceeds to Mirum from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $48.0 million.

In addition, Mirum has granted the underwriters a 30-day option to purchase up to an additional 360,000 shares of common stock at the public offering price less underwriting discounts and commissions. The offering is expected to close on January 13, 2020, subject to satisfaction of customary closing conditions.

Citigroup, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering. Raymond James is acting as lead manager. Roth Capital Partners is acting as co-manager.

The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at (800) 831-9146; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, New York, NY 10055, by email at ecm.prospectus@evercore.com or by phone at (888) 474-0200.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on January 8, 2020. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005918/en/

Source: Mirum Pharmaceuticals, Inc.

Media Contact:
Heidi Chokeir, Ph.D.
Canale Communications
619-203-5391
heidi@canalecomm.com

Investor Contact:
Ian Clements, Ph.D.
650-667-4085
ir@mirumpharma.com

Header Menu

  • Who We Are
  • About Mirum
  • Leadership
  • Board of Directors
  • Programs
  • Pipeline
  • Maralixibat
  • Volixibat
  • Publications & Presentations
  • Patients & Families
  • Clinical Trials
  • Expanded Access
  • Progressive Familial Intrahepatic Cholestasis (PFIC)
  • Alagille Syndrome (ALGS)
  • Biliary Atresia (BA)
  • Intrahepatic Cholestasis of Pregnancy (ICP)
  • Primary Sclerosing Cholangitis (PSC)
  • Investors & Media
  • News Releases
  • Events and Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Shareholder Services
  • Careers
  • Contact Us
© 2021 – Mirum Pharmaceuticals, Inc.
Scroll to top
  • Facebook
  • Twitter
  • LinkedIn